The director of the Hematology/Oncology Fellowship Training Program at Fox Chase Cancer Center discusses palliative care training for hematology/oncology fellows and highlights a pilot study aimed at improving this area of training.
Epcoritamab produced responses in older patients with newly diagnosed large B-cell lymphoma.
Dr. Amer Zeidan presents interim Phase 1a results from the KOMET-007 trial, demonstrating the safety and robust clinical activity of ziftomenib combined with intensive chemotherapy…
Brexu-cel led to an ORR of 91% in patients with relapsed/refractory MCL who were naive to BTK inhibitors, according to new data from the ZUMA-2…
If approved, durvalumab will be the first and only perioperative immunotherapy regimen available for the treatment of patients with muscle-invasive bladder cancer in this curative-intent…
An abstract is unavailable.
BGB-16673 monotherapy showed early activity and a tolerable safety profile in relapsed/refractory Waldenström macroglobulinemia, CLL, and SLL.
Hematologic oncology specialists review recent data from the PERSEUS trial analyzing minimal residual disease in patients with newly diagnosed multiple myeloma who receive DARA-VRd.
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Edited by Associate Editor Michael Hallek and Podcast Editor Laurie H. Sehn, this Review Series highlights the biologic features of, clinical phenotype of,
